134 related articles for article (PubMed ID: 15687357)
1. Scientists hopeful as they uncover molecular clues to prostate cancer.
Vanchieri C
J Natl Cancer Inst; 2005 Feb; 97(3):168-9. PubMed ID: 15687357
[No Abstract] [Full Text] [Related]
2. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
[TBL] [Abstract][Full Text] [Related]
3. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin's resurrection: a new way to target the cancer cell cycle.
Garber K
J Natl Cancer Inst; 2001 Oct; 93(20):1517-9. PubMed ID: 11604470
[No Abstract] [Full Text] [Related]
5. Synthetic lethality: killing cancer with cancer.
Garber K
J Natl Cancer Inst; 2002 Nov; 94(22):1666-8. PubMed ID: 12441317
[No Abstract] [Full Text] [Related]
6. Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells.
Li P; Nicosia SV; Bai W
J Biol Chem; 2001 Jun; 276(23):20444-50. PubMed ID: 11278645
[TBL] [Abstract][Full Text] [Related]
7. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
8. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
[TBL] [Abstract][Full Text] [Related]
9. [Molecular genetic mechanisms of drug resistance in prostate cancer].
Krasnov GS; Dmitriev AA; Sadritdinova AF; Volchenko NN; Slavnova EN; Danilova TV; Snezhkina AV; Melnikova NV; Fedorova MS; Lakunina VA; Belova AA; Nyushko KM; Alekseev BY; Kaprin AD; Kudryavtseva AV
Mol Biol (Mosk); 2015; 49(5):716-27. PubMed ID: 26510590
[TBL] [Abstract][Full Text] [Related]
10. The biology and clinical relevance of the PTEN tumor suppressor pathway.
Sansal I; Sellers WR
J Clin Oncol; 2004 Jul; 22(14):2954-63. PubMed ID: 15254063
[TBL] [Abstract][Full Text] [Related]
11. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
[TBL] [Abstract][Full Text] [Related]
12. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma.
Koksal IT; Dirice E; Yasar D; Sanlioglu AD; Ciftcioglu A; Gulkesen KH; Ozes NO; Baykara M; Luleci G; Sanlioglu S
Urol Oncol; 2004; 22(4):307-12. PubMed ID: 15283888
[TBL] [Abstract][Full Text] [Related]
13. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells.
Lin HK; Hu YC; Lee DK; Chang C
Mol Endocrinol; 2004 Oct; 18(10):2409-23. PubMed ID: 15205473
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
Galanis E; Buckner JC; Maurer MJ; Kreisberg JI; Ballman K; Boni J; Peralba JM; Jenkins RB; Dakhil SR; Morton RF; Jaeckle KA; Scheithauer BW; Dancey J; Hidalgo M; Walsh DJ;
J Clin Oncol; 2005 Aug; 23(23):5294-304. PubMed ID: 15998902
[TBL] [Abstract][Full Text] [Related]
15. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.
Podsypanina K; Lee RT; Politis C; Hennessy I; Crane A; Puc J; Neshat M; Wang H; Yang L; Gibbons J; Frost P; Dreisbach V; Blenis J; Gaciong Z; Fisher P; Sawyers C; Hedrick-Ellenson L; Parsons R
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10320-5. PubMed ID: 11504907
[TBL] [Abstract][Full Text] [Related]
16. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
[TBL] [Abstract][Full Text] [Related]
17. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo.
Kwon CH; Zhu X; Zhang J; Baker SJ
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12923-8. PubMed ID: 14534328
[TBL] [Abstract][Full Text] [Related]
18. [PTEN expression in endometrial cancer and the prognosis].
Kanamori Y; Uegaki K; Kigawa J; Terakawa N
Nihon Rinsho; 2004 Oct; 62 Suppl 10():406-9. PubMed ID: 15535277
[No Abstract] [Full Text] [Related]
19. MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer.
Koul D; Shen R; Garyali A; Ke LD; Liu TJ; Yung WK
Int J Oncol; 2002 Sep; 21(3):469-75. PubMed ID: 12168088
[TBL] [Abstract][Full Text] [Related]
20. Perspectives in central nervous system malignancies.
Stummer W
IDrugs; 2006 Jun; 9(6):412-4. PubMed ID: 16752310
[No Abstract] [Full Text] [Related]
[Next] [New Search]
